Who is sponsoring NCT02492438?

NCT02492438 is sponsored by AZ Sint-Jan AV.

What condition does NCT02492438 study?

NCT02492438 studies Chronic Kidney Failure.

What drugs are being tested in NCT02492438?

Interventions: PPV23 vaccination or PCV13 vaccination.

What is the status of NCT02492438?

NCT02492438 is currently COMPLETED.

Last reviewed 2015-07-05 · How we verify

Immunogenicity and Safety of the 13-valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients That Are 23-valent Pneumococcal Polysaccharide Vaccine Naive and Pre-immunized.

NCT02492438 Phase 4 COMPLETED

To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

Details

Lead sponsor	AZ Sint-Jan AV
Phase	Phase 4
Status	COMPLETED
Enrolment	154
Start date	2013-02
Completion	2014-03

Conditions

Chronic Kidney Failure

Interventions

PPV23 vaccination or PCV13 vaccination

Primary outcomes

Antibody response after vaccination to involved serotypes measured by OPA and ELISA — 52 weeks after vaccination

Countries

Belgium